Clinical Trials

Clinical Trials / Research

Newark Beth Israel Medical Center has a long standing history of participating in research for cancer and blood disorders. At present we conduct a wide variety of clinical trials in cancer and blood disorders.

For more information about our clinical trials, please call 973.926.7230

Open Protocols

Breast Cancer

We are a member of NSABP and have open clinical trials.

cancer research

NSABP B-37/IBCSG 27-02 A Randomized Clinical Trial of Adjuvant Chemotherapy For Radically Resected Loco-Regional Relapse of Breast Cancer

NSABP B-39 A Randomized Phase III Study of Conventional Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) for Women with Stage 0, I, or II Breast Cancer (Open, enrollment via radiation oncology)

NSABP B-40 A Randomized Phase III Trial of Neoadjuvant Therapy in Patients with Palpable and Operable Breast Cancer Evaluating the effects on Pathologic Complete Response (pCR) of Adding Capecitabine or Gemcitabine to Docetaxel when Administered Before AC with or without Bevacizumab and Correlative Science Studies Attempting to Identify Predictors of High Likelihood for pCR with Each of the Regimens

NSABP B-41 A Randomized Phase III Trial of Neoadjuvant Therapy for Patients with Palpable and Operable HER2 Positive Breast Cancer Comparing the Combination of Trastuzumab Plus Lapatinib Administered with Weekly Paclitaxel Following AC accompanied by Correlative Science Studies to Identify Predictors of Pathologic Complete Response.

NSABP B-42 A Clinical Trial to Determine the Efficacy of Five Years of Letrozole Compared to Placebo in Patients Completing Five Years of Hormonal Therapy Consisting of an Aromatase Inhibitor (AI) or Tamoxifen Followed by an AI in Prolonging Disease-Free Survival in Postmenopausal Women with Hormone Receptor Positive Breast Cancer (B-44 Optional Registration Program Closed Sept 2008)

NSABP B-44-I (The Beth Trial): A Multicenter Phase III Randomized Trial of Adjuvant Therapy for Patients with HER-2 Positive Node-Positive or High Risk Node Negative Breast Cancer Comparing Chemotherapy Plus Trastuzumab with Chemotherapy Plus Trastuzumab Plus Bevacizumab

STUDY #0502: “Thyroid function and breast cancer: A pilot study to estimate the prevalence of thyroid dysfunction in women diagnosed with breast cancer and the magnitude of change in thyroid function post-chemotherapy

PACCT-1: Program for the Assessment of Clinical Cancer Tests: TailoRx - Trials Assigning Individualized Options for Treatment

ECOG 5103: A Double-Blind Phase III Trial of Doxorubicin and Cyclophosphamide Followed by Paclitaxel with Bevacizumab or Placebo in Patients with Lymph Node Positive and High Risk Lymph Node Negative Breast Cancer

GI Cancer

ECOG 5204: Intergroup Randomized Phase III Study of Postoperative Oxaliplatin, 5-Fluouracil and Leucovorin VS Oxaliplatin, 5-Fluouracil, Leucovorin and Bevacizumab for Patients with Stage II or III Rectal Cancer Receiving Pre-operative Chemoradiation

NSABP R-04 A Clinical Trial Comparing Preoperative Radiation Therapy and Capecitabine with Preoperative Radiation Therapy and Continuous Intravenous Infusion (CVI) of 5-Fluorouracil (5-FU) in the Treatment of Patients with Operable Carcinoma of the Rectum

CALGB –SWOG C80405: A Phase III Trial of Irinotecan/5-FU/Leucovorin or Oxaliplatin/5-FU/Leucovorin with Bevacizumab or Cetuximab (C225), or with the Combination of Bevacizumab and Cetuximab for Patients with Untreated Metastatic Adenocarcinoma of the Colon or Rectum (HOLD)

CALGB – C80403/E1206: Randomized Phase II Study of ECF-C, IC-C, or FOLFOX-C in Metastatic Esophageal and GE Junction Cancer

Lung Cancer

E1505: A phase III randomized trial of adjuvant chemotherapy with or without Bevacizumab for patients with completely resected stage 1B(>4cm)-IIIA non-small cell lung cancer (NSCLC)

Any New Cancer Diagnosis

HLMCC 0501 Stress Management – Usual psychosocial care vs. self administered stress management plus usual psychosocial care

***HISPANIC PARTICIPANTS ONLY***
NON-HISPANIC ENROLLMENT COMPLETE

Hematologic Cancer

C05009: Randomized Phase IIIB Study of Three Treatment Regimens in Subjects with Previously Untreated Multiple Myeloma Who are not Considered Candidates for High-Dose Chemotherapy and Autologous Stem Cell Transplantation: Velcade (Bortezomib), Thalidomide and Dexamethasone (VTD) Versus Velcade and Dexamethasone (VD) Versus Velcade, Melphalan and Prednisone (VMP) (PHARMACEUTICAL SPONSORED)

ECOG 3404: Response-Adapted Therapy for Aggressive Non-Hodgkin’s Lymphomas Based on Early FDG – PET Scanning: Rituximab and Combination Chemotherapy in Treating Patients with Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non Hodgkin’s Lymphoma

Patient & Clinician Videos

For more information about clinical trials, watch these videos from the American Cancer Society:

Exploring the Options: Clinical Trials: in this video, learn more about cancer clinical trails options from the American Cancer Society.

Raising Awareness about Clinical Trials: A Video for Clinicians:in this video, learn more about how clinicians can help raise awareness for cancer clinical trails options from the American Cancer Society.

[ top ]